Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 3/20 | 0.41 |
| ▸ | CTSK | P43235 | 3/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | CCKAR | P32238 | 4/20 | 0.40 |
| ▸ | CCKBR | P32239 | 4/20 | 0.40 |
| ▸ | ACE | P12821 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6515094 | 0.80 | AKT1 (0.56) | CTSSCTSKCTSLCTSBAKT1 | |
| SCHEMBL5403799 | 0.72 | CTSS (0.53) | CTSSCTSKCTSLCTSBAKT1 | |
| SCHEMBL5873366 | 0.70 | CTSS (0.60) | CTSSCTSKCTSLCTSBAKT1 | |
| SCHEMBL1764798 | 0.68 | CTSS (0.64) | CTSSCTSKCTSLCTSBAKT1 | |
| SCHEMBL6162474 | 0.68 | CTSS (0.64) | CTSSCTSKCTSLCTSBAKT1 | |
| SCHEMBL5403879 | 0.68 | CTSS (0.58) | CTSSCTSKCTSLCTSBAKT1 | |
| SCHEMBL6019868 | 0.67 | CTSS (0.66) | CTSSCTSKCTSLCTSBAKT1 | |
| SCHEMBL6790744 | 0.67 | CTSS (0.66) | CTSSCTSKCTSLCTSBAKT1 | |
| SCHEMBL7311950 | 0.67 | CTSS (0.68) | CTSSCTSKCTSLCTSBAKT1 | |
| SCHEMBL4526753 | 0.67 | CTSS (0.68) | CTSSCTSKCTSLCTSBAKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| WO-2005028474-A2 | PYRAZOLOQUINOLINE DERIVATIVES AS CHK-1 INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245563-A1 | Chk-1 inhibitors | CHKA, CHKB, CHEK1 | CTSS 983/4885CTSK 102/4885CTSL 919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.